Skip to Content Skip to Search

Research and Development

Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients

We are a science-led global healthcare company. Our purpose is to help people do more, feel better, live longer.

We deliver our long-term priorities of Innovation, Performance and Trust through each of our three businesses which discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Our Pharmaceuticals research is focused on science related to the immune system, the use of human genetics, and the application of advanced technologies such as functional genomics, artificial intelligence and machine learning. Our approach is driven by the “multiplier effect” of Science x Technology x Culture. It will help us to accelerate the pace at which we develop and deliver transformational medicines, prioritising those molecules with a higher probability of success and terminating less promising programmes. It also enables us to increase our focus on specialty medicines in areas such as oncology.

In our Vaccines business, we balance our focus on a robust pipeline with the active life-cycle management of our existing vaccines, seeking to protect more people through expanding indications and delivering our vaccines to new geographies. Our Innovation ambition is to lead the industry by disrupting the discovery, development and manufacturing of vaccines. We will focus on accelerating key assets in our pipeline and looking at innovative technologies so that we can unlock potential in emerging fields. Using our industry-leading science, we will accelerate the delivery of our most promising assets to serve the greatest unmet medical need. We want to change the world with our science.

Our Consumer Healthcare R&D organisation develops products in five categories: Oral Health, Pain Relief, Respiratory, Nutrition and Gastrointestinal and Skin Health. Our focus is on building a strong, competitive pipeline of consumer-led, science-based innovation. On 1 August 2019 we announced that we'd completed our transaction with Pfizer to combine our consumer healthcare businesses into a new world-leading Consumer Healthcare Joint Venture. Within three years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find out more

Key facts about R&D at GSK in Belgium

  • 2,000

    researchers working in research and development for Vaccines

  • 20

    vaccines currently in development

  • 65

    years of innovation in vaccines

  • 9,000

    employees on 3 sites

To carry on our success in finding new products, of the >9,000 employees working in Belgium, we have 1,800 people working in research & development (R&D) dedicated to finding new ways to improve the treatment of diseases and illnesses.

GSK's historical site and R&D center in Belgium is located in Rixensart, which is why the majority of our vaccine names end in "-RIX". GSK has invested heavily in R&D and in its Belgian infrastructure over the last 10 years. The most recent investment was made in March 2021 with 330 million euros dedicated to the Wavre site.

Join us

In R&D we believe that outstanding talent attracts outstanding talent, so we demand, develop and retain the very best people. If you want to work in a culture that incentivizes courageous and smart risk-taking to help deliver the next generation of transformational medicines, vaccines and consumer healthcare products please visit our careers section.

Visit Careers

Find out more about our global R&D

Read more about our global focus areas, trials in people, use of animals and partnerships on our global website.